Received Mar 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | Y3ME2 | — |
patients were administered with expired doses of Havrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 16-year-old male patient who received HAV (Havrix pediatric) (batch number Y3ME2, expiry date 23-FEB-2025) for an unknown indication. On 27-FEB-2025, the patient received the 1st dose of Havrix pediatric. On 23-FEB-2025, an unknown time after receiving Havrix pediatric, the patient experienced expired vaccine used (Verbatim: patients were administered with expired doses of Havrix). The outcome of the expired vaccine used was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 28-FEB-2025 The patient was administered with expired dose which led expired vaccine used. This was the first Hepatitis A vaccine for the patient. The reporter consented to follow up. This case was linked with case US2025025535 reported by the same reporter, for different patient.; Sender's Comments: US-GSK-US2025025535:Same reporter/Different patient